Franjo Grotenhermen completed his medical studies and received his doctorate (M. D.) in Cologne. His fields of activity included internal medicine, surgery and naturopathy. He runs a medical practice in Steinheim (Westphalia) with a focus on therapy with cannabis and cannabinoids. Grotenhermen is Executive Director of the German Arbeitsgemeinschaft Cannabis als Medizin (ACM), Executive Director of the International Association for Cannabinoid Medicines (IACM) and author of the IACM Bulletin, which is published bi-weekly since 2000 in several languages on the IACM website. Grotenhermen is an employee of the Cologne-based nova-Institut, co-owner of Endoxo GmbH (founded in 2019) and Head of Scientific Committee of MYCB1 (since 2019). He is Honorary President of the Union Francophone pour les Cannabinoïdes en Médecine (UFCM) and member of the Scientific Advisory Board of Portugal Medical Cannabis (PTMC). He received the following awards: Hemp Prize 1999 of Cannabusiness, IACM 2011 Special Award, ICBC 2018 Lifetime Achievement Award, Robert Newman Memorial Prize 2018 of Akzept e.V.